The future of comprehensive cancer care
Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.
“tests like these assure patients get the best cancer care, as clinicians use these results to determine the best treatment strategies based on the patients tumor profile - It's really that simple.”
Benjamin Kipp, Ph.D., chair of the Division of Laboratory Genetics and Genomics
Our difference
News and updates
The latest
Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.
Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Pritt and Dr. Morice discuss their new roles at Mayo Clinic and update listeners on the latest legislative news impacting the laboratory and diagnostic industries. They also highlight the launch of MayoComplete, Mayo Clinic Laboratories’ robust suite of oncology and hematology testing that uses next-generation sequencing to identify and evaluate presence of mutations.
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.
In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.
In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.
Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
As a two-time brain tumor survivor, Alex Kraatz has been through more harrowing medical experiences in his 34 years than most people face in a lifetime. But Alex’s fighting spirit, coupled with precision laboratory testing and cutting-edge treatments, have propelled him forward, keeping him hopeful despite the odds.
This unique Mayo Clinic resource offers a novel portal into the study of gene mutations before they cause breast cancer.
In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.